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health insurance status were associated with differential levels of antidepressant adher-
ence and associated health expenditure. Hispanic ethnicity was associated with 
decreased antidepressant adherence compared to non-Hispanic white (β = 12.53, P < 
0.05) and other ethnicities (β = 28.27, P < 0.01). Patient who were covered by public 
insurance had better PDC compared to uninsured patients (β = 16.23, P < 0.05). 
Patient who were covered by private insurance spent more on MDD-speciﬁ c drug 
compared to uninsured patients (β = 0.36, P < 0.05). Higher antidepressant adherence 
was associated with higher MDD-speciﬁ c drug expenditure (β = 0.03, P < 0.01). Use 
of innovative antidepressants such as SSRIs and SNRIs was associated with an increase 
in MDD-speciﬁ c drug expenditure. CONCLUSIONS: Differences in antidepressant 
adherence and health care spending across patient factors could have important policy 
implications for drug formularies and health disparities. Solutions for gaps between 
optimal and suboptimal health care for patient mental health caused by systematic 
differences in sociological factors need to be well tailored. We need policy makers to 
be engaged in designing effective policy interventions to improve patient medication 
adherence, and to fund cost-effectiveness studies to improve patient outcomes and in 
turn, reduce associated health expenditure.
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OBJECTIVES: Innovative antidepressants have been widely adopted. However, the 
differences in patient factors and antidepressant use, and associated patient health and 
work outcomes were not jointly studied. This study was trying to understand how 
patient factors and antidepressant utilization were associated with patient employment 
durations and quality of life. METHODS: A retrospective cross-sectional study was 
conducted using the 2004–2007 Medical Expenditure Panel Survey (MEPS) database. 
Proportional hazard duration models were used to examine MDD patient’s employ-
ment duration. Linear regression models were implemented to study the impacts of 
MDD patient factors and antidepressant utilization on associated patient physical and 
mental health status. RESULTS: Differences in employment duration across several 
patient factors were found. Cox proportional hazard model showed that, compared 
to uninsured patients, MDD patients covered by private insurance had a lower level 
of hazard of job termination (hazard ratio = 0.15, P < 0.01). Patients who were in 
better physical health conditions had a lower level of hazard of job termination 
(hazard ratio = 0.96, P < 0.01). Results from OLS regressions showed that, compared 
to patient without antidepressant pharmacotherapy for MDD treatment, patients who 
took innovative antidepressants such as SSRIs/SNRIs and other newer ones had a huge 
increase in MCS (β = 11.35, P < 0.01). In addition, better antidepressant adherence 
was signiﬁ cantly associated with an increase of MCS (β = 0.10, P < 0.01). CONCLU-
SIONS: This study suggested that effective policy interventions were needed for 
improving medication adherence, and the design of prescription drug beneﬁ t within 
health insurance should be tailored considering its associations with patient factors 
and related improvement in health status according to the ﬁ ndings of this study. We 
need policy makers to be engaged in designing effective policy interventions to improve 
patient medication adherence, which may in turn improve patient health status and 
labor market participation.
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OBJECTIVES: To assess cost-of-illness and patient-relevant outcomes in patients with 
dementia in different settings in the German health system. METHODS: 600 patients 
with dementia were recruited at 1) a university hospital; 2) general practitioners; 3) 
ofﬁ ce-based neurologists; 4) a regional psychiatric hospital; and 5) in long-term care 
facilities. Socio-demographic, economic and clinical parameters were assessed using a 
standardized questionnaire. Disease severity was measured by means of the Minimen-
tal Status Examination (MMSE) and the Alzheimer’s Disease Assessment Scale. Neu-
ropsychiatric status was assessed with the Geriatric Depression Scale, the 
Neuropsychiatric Inventory and the Alzheimer’s Disease Cooperative-Study-Activities 
of Daily Living. Patient’s quality of life was reported by the patient and also by the 
caregiver (employing the EuroQol and the QoL-AD instruments). RESULTS: For an 
interim analysis, 278 patients (180 female, 98 male) were available. Mean age was 
78.2 yrs and mean disease duration was 4.5 yrs (SD 3.9). On average, care was needed 
for 3.0 yrs (SD 3.1). Cognitive impairment was severest in institutionalized patients 
(MMSE 12.2 pts SD 8.2) compared to the mean of all patients (MMSE 16.9 Pts). 
Mean EQ VAS values were 60.5 pts (SD 20.2). Disease-speciﬁ c QoL-AD health status 
mean was 30.2 (SD 5.6). Health status was rated highest in long-term care facilities 
(EQ VAS) and at ofﬁ ce-based neurologists (QoL-AD). In all severity stages patients 
rated their own health status (Qol-AD) better than their relatives. The costs of anti-
dementia drugs were c45,000 per 3 months. Memantine accounted for 61%. a total 
of 41% of the patients received Memantine whereas 45% of the patients received no 
anti-dementia medication. CONCLUSIONS: Health status is considerably impaired 
in patients with dementia and their caregivers. Interestingly, caregivers often appraise 
patients’ Quality of life worse than the patients themselves. Altogether, our results 
indicate a considerable under-supply with anti-dementia drugs.
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OBJECTIVES: The Zarit Burden Inventory (ZBI) is a 22-item self-report scale fre-
quently used to asess patients’ caregiver burden on several dimensions. As a multidi-
mensional instrument the interpretation of its total score is sometimes unclear. Our 
aim was to obtain a short-ZBI unidimensional scale based on Item Response Theory 
(IRT) approaches. METHODS: The validation sample comprised 246 caregivers of 
patients diagnosed with dementia and recruited for an ongoing multi-center random-
ized clinical trial on the efﬁ cacy of psychoeducational interventions (EDUCA-2 trial). 
The pre-randomization 22-item ZBI was analyzed according to the Samejima’s graded 
response model to select the more informative items. The dimensionality of the scale 
was further tested with Conﬁ rmatory Factor Analysis (CFA). Finally, discriminant 
validity was assessed by Receiving Operator Characteristic (ROC) analysis and the 
Area Under the Curve (AUC) contrasting the short scale total score against the psy-
chological distress criterion evaluated with the General Health Questionnaire 28-item 
at 5/6 cut-off. RESULTS: A 12-item short-ZBI was selected. It covered 87% of the 
total 22-item ZBI information and showed appropriate item curve characteristics 
according to the Samejima’s model. The short-ZBI had an internal reliability of 0.89 
(Cronbach’s alpha), and was compatible with a unidimensional latent structure for 
the burden construct (CFI = 0.99; RMSEA = 0.05). According to the GHQ-28 cut-off 
131 caregivers (53% of the total sample) could be considered at high risk for develop-
ping psychological distress. The discriminant validity of the short-ZBI scale against 
that criterion was good (AUC = 0.84, 95% CI = 0.79 to 0.89) and not signiﬁ cantly 
different from the parental 22-item ZBI (p = 0.85). CONCLUSIONS: We have found 
good psychometric properties for the short-ZBI scale derived from IRT. Its unidimen-
sionality might be important to enhance its interpretation. Further psychometric 
studies, mainly on its sensitivity to change are now warranted.
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OBJECTIVES: The literature indicates that social support is protective of relapse for 
adolescents treated for substance use disorder (SUD). Unfortunately, no standard 
measure of social support exists. The objective of this research is to use factor analysis 
to elucidate the underlying factor structure of a 14-item social support scale for use 
in outcomes assessment in this treatment population. METHODS: Subjects are 517 
adolescents discharged from primary substance abuse treatment from 2004–2008. The 
data is from research conducted between 6 and 12 months post discharge via a 234-
item questionnaire that included the 14-item social support scale. The scale has ques-
tions that assess the degree to which the adolescent’s social contacts conform to norms 
of positive behavior and therefore foster non-use and recovery. The response rate was 
62 percent. RESULTS: The factorability of the scale was assessed by Keiser-Meyer-
Olkin statistic (it was 0.727, > the recommended 0.6) and by Bartlett’s test of spheric-
ity which was signiﬁ cant (x2 = 1066.89, p = 0.00001). The scale was decomposed by 
principal component factor analysis and three factors emerged. Initial Eigen values 
explained 65.6, 23.1 and 11.3 percent of the variance, respectively. Final factor solu-
tions were examined using varimax, oblimin and promax rotations with 3, 4, 5 & 6 
solutions, respectively. a three-factor solution via promax explaining 99 percent of 
the variance emerged as the best solution although results were similar using the other 
rotations. Factor 1 yielded ten items that are attributes of a peers’ potential to be 
positive a or negative inﬂ uence and thus supportive of recovery. The three items in 
Factor 2 related to emotional dimensions of social support. Factor 3 contained two 
items indicating a recovering adolescent’s ability to seek-out and establish positive 
social contacts. CONCLUSIONS: This scale is useful as a standard measure of social 
support which is an important aspect of treatment success.
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OBJECTIVES: In deciding about coverage of new medical technology, multiple clini-
cal outcomes are used to support reimbursement claims. Neither the real world value 
nor the relevance of these outcome measures for patients is systematically assessed. 
Hence, there is growing interest in the use of patient-reported outcome measures. 
Multi-criteria decision analysis, like the analytic hierarchy process (AHP), is a tech-
nique to elicit patient preferences. In the present study we used AHP to prioritize 
patient relevant endpoints related to the use of antidepressants in major depression. 
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METHODS: Patient relevant endpoints of treatment (remission of depression, 
response to treatment, no relapse, serious adverse events, adverse events, social func-
tion, anxiety, pain, cognitive function) were prioritized using pairwise comparisons of 
these outcomes. In two separate groups, twelve patients and seven experts judged on 
a 9 point scale the relative importance of pairs of two outcome measures. The geo-
metric mean of these judgments was used to derive weighting factors for the outcome 
measures (scale 0–1). RESULTS: Of all outcome measures, patients rated response to 
treatment highest (0.32), while experts rated remission of depression highest (0.48). 
Adverse events were all rated lowest by patients as well as by experts, and disease-
speciﬁ c quality of life domains such as social function (0.11 & 0.09), anxiety (0.12 
& 0.05) and cognitive function (0.13 & 0.06) were rated in between. CONCLU-
SIONS: The most important outcome measures according to the patients are, in order 
of decreasing importance: response, cognitive function, no anxiety, social function, no 
relapse, no adverse events, and remission. The AHP appears to be suitable in gaining 
an overview of the importance of patient relevant outcome measures. An additional 
advantage of AHP is that the group discussions offer insight in the question why the 
endpoints are important.
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OBJECTIVES: Outcomes research in patients with schizophrenia should take into 
account the subjective interpretation of the mood and physical changes accompanying 
medication. Those changes inﬂ uence the behavioural response to treatment and ulti-
mately the patient’s clinical outcome as mediated by his treatment compliance. Our 
aim was to assess the relationship between a speciﬁ c well-being measure, the SWN-K20 
that presents a general and 5 speciﬁ c measurement subdomains (mental functioning, 
social integration, emotional regulation, physical functioning, and self-control), and 
the 8 domains of the SF-36 v1 as a general quality of life measure. METHODS: The 
validation sample for this study comprised 97 patients diagnosed with schizophrenia 
and who were rated as clinically stable at the moment of the study (1 week test-retest 
intraclass correlation coefﬁ cient for clinical symptoms = 0.96). The patients were 
recruited as part of a multicenter psychometric trial to validate the SWN-K20 in 
Spanish. The associations between the domains of the SWN-K20 and the SF-36 were 
evaluated by the Spearman’s rank correlation test. RESULTS: All correlations among 
domains were positive and most were statistically signiﬁ cant (p < 0.05). As expected 
the bodily pain domain of the SF-36 presented the lower correlations with the 
SWN-K20 (rho range of 0.10 to 0.25), whereas the other 7 domains correlated sig-
niﬁ cantly with the total SWN-K20 score (rho range 0.49 to 0.60, all p < 0.001). 
Overall the largest correlations were obtained between the SWN-K20 and the SF-36 
domains of general health (rho = 0.53), mental health (rho = 0.60), and vitality (rho 
= 0.54). CONCLUSIONS: The positive but nevertheless moderate correlations 
observed between a speciﬁ c well-being scale, as the SWN-K20, and a general quality 
of life scale, as the SF-36, supports the inclusion of speciﬁ c and diagnose-tailored 
instruments for outcome assessments of patients with schizophrenia.
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OBJECTIVES: Understand features of an electronic device that allow a marked 
improvement in the quality of collected data; the importance of improved data quality 
leading to enhanced patient safety and drug labeling; populations best suited for paired 
PRO and cognitive measurement technologies; important practical considerations for 
implementation in clinical trials including training and compliance; the potential for 
using real-time parallel data for adverse event safety monitoring. METHODS: This 
session discusses using ePRO and biometric technology for parallel data capture 
emphasizing advantages, disadvantages, execution, and ways to leverage these data. 
The session will review PRO and cognitive testing technologies, including comparisons 
of devices that combine physiological measures with a patient interface with systems 
that use separate PRO input and biometric devices. RESULTS: Assessing a treatment’s 
ability to enhance or prohibit reduction of cognitive processing efﬁ ciency is an emerg-
ing study in the pharmaceutical industry. Case studies examine how the use of cogni-
tive function tests in combination with ePRO can enhance the data collection so drug 
effects otherwise unidentiﬁ ed can be determined. The speaker will discuss the future 
of ePRO combined with biometric measurements as a standard of clinical research. 
CONCLUSIONS: Clinical trial endpoints can involve collection of physiologic and 
patient-reported outcome data; a combination of subjective and objective data. Elec-
tronic forms of information capture assure trial efﬁ ciencies including edit checks and 
shorter time to database lock. ePRO provides time-stamped, legible and complete data 
from subjects. Biometric devices capture the physiological measurements. Typically, 
cognition data have been collected from patients separately from PRO data during 
clinical trials, increasing respondent burden and risk of error such as transposing 
manually entering data. The use of ePRO and biometric devices, evolution of data 
transmission technology, and greater technologic sophistication of consumers, provide 
an opportunity for parallel electronic data capture, simultaneously capturing and 
transmitting physiologic and PRO parameters in clinical studies.
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OBJECTIVES: Our intention was to investigate the prevalence of Eating Disorder and 
Body Dysmorphic Disorder in patients diaghnosed with depression, anxietay and 
borderline personality disorder by gender, using controll groups. METHODS: The 
reserach was 2009 at the Department of Phsyciatry of Szigetvár Hospital (Hungary). 
Eating Disorder Inventory was used. a self-made questionnaire aimed the body mass, 
body height and several demographic data. Inclusion criteria: ones between 18 and 
50 years age, and according to BNO F32-F34 (depression), F41 (anxiety), F6030 
(borderline personality disorder) diagnoses. Control group: participants with age 
between 18 and 50 years like that, who do not stand under a psychiatric treatment. 
The statistical analysis consisted of two sample T test, χ2-probe. RESULTS: The target 
group’s number was 82, the control group 85. In the “The feeling of the insufﬁ ciency” 
(P < 0.001), “Interpersonal distrust” (P < 0.005), “Interoceptive consciousness” (P < 
0.001) scales, the members of the control group from all three psychiatric patient 
groups reached a signiﬁ cantly lower score away. In the “Bulimia” scale there was a 
signiﬁ cantly lower score in the control group as well than the borderline in a group 
(P < 0.005), and here I found a signiﬁ cant difference between the members of two 
psychiatric groups: the anxious group reached a lower score, compared with the 
borderline group (P < 0.001). CONCLUSIONS: The three psychiatric patient groups 
did not attain the threshold value onto one of the eating disturbances relevant scales 
neither There is not a direct, causal contact between the examined psychiatric clinical 
pictures. The men’s higher result achieved on the „Bulimia” scale relates rather onto 
the binge eating disorder.
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OBJECTIVES: The primary objective of this analysis was to compare ﬁ ve different 
clinical measures and their impact on economic modelling. Clinical measures com-
pared are the Mini-Mental State Examination (MMSE), the Cognitive Component 
Score (CCS), the Functional Component Score (FCS) the Behaviour Component Score 
(BCS), and the Dependence Scale (DS). METHODS: The MMSE, CCS, FCS, BCS and 
DS were compared in their ability to explain variation in clinical outcomes, economic- 
and other utilized resources, caregiver burden (Zarit Scale) and caregiver QoL 
(EQ-5D) using univariate (Pearson correlations) and multivariate (linear regression) 
analyses. Data on subjects and caregivers was obtained from multiple centres in Spain. 
RESULTS: In total 394 subjects, males and females aged 50 to 93 years old with mild 
cognitive impairment to severe dementia were included in this study. CCS, FCS, BCS 
and DS were moderately correlated with MMSE, with Pearson correlations ranging 
from −0.26 for BCS to −0.56 for CCS. These four clinical measures were also mod-
erately correlated with medical costs, Zarit Scale and EQ-5D while MMSE was not. 
These measures also performed better in explaining variation in medical costs, Zarit 
Scale and caregivers’ EQ-5D. MMSE performed better explaining variation in the 
number of concomitant conditions and caregiver time (hours per day). CONCLU-
SIONS: The CCS, FCS, BCS and DS are better predictors in modelling AD progression 
on a higher number of variables including medical costs, caregivers’ burden and 
caregivers QoL than the MMSE.
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OBJECTIVES: Aripiprazole has been claimed to have a beneﬁ cial effect on cognition 
with an emphasis on verbal functioning in schizophrenic patients. a prospective, 
multicenter, open-label study of Aripiprazole was set to evaluate the effect on quality 
of life, in relation to illness severity and cognitive functioning of a treatment with 
aripiprazole in schizophrenic patients. METHODS: A total of 363 schizophrenic 
patients from 18 to 65 years, treated with different typical and atypical antipsychotics 
or had no previous treatment, were switched to aripiprazole after a 2 week washout 
period. Quality of life was assessed by use of the Quality of Life Enjoyment and 
Satisfaction Questionnaire (QLESQ) at 3 separate test moments in a 12 weeks period. 
